NRX Pharmaceuticals
NRXP
37 hedge funds and large institutions have $2.18M invested in NRX Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 5 closing their positions.
254% more call options, than puts
Call options by funds: $237K | Put options by funds: $67K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
9% more funds holding
Funds holding: 34 → 37 (+3)
0.99% less ownership
Funds ownership: 1.54% → 0.55% (-0.99%)
91% less capital invested
Capital invested by funds: $25.1M → $2.18M (-$23M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$390K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$202K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$183K |
| 4 |
BlackRock
New York
|
+$167K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$15.3M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.53M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$765K |
| 4 |
Renaissance Technologies
New York
|
-$139K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$50K |
NRXP Hedge Fund Activity: Q2 2022 in Review
37 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q2 2022, worth a combined $2.18M — down 91% from $25.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NRXP positions and 5 closed out — a net gain of 3 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $390K. The largest seller was Armistice Capital, exiting entirely with an estimated $15.3M sold.
- 37 institutional investors held NRX Pharmaceuticals (NRXP) as of Q2 2022, up from 34 in Q1 2022.
- Funds reported $2.18M of NRX Pharmaceuticals stock for Q2 2022, down 91% quarter-over-quarter.
- 8 funds opened new NRX Pharmaceuticals positions in Q2 2022 and 5 closed out, a net change of +3 holders.
- The largest NRX Pharmaceuticals buyer in Q2 2022 was Millennium Management, an estimated $390K added.
- The largest NRX Pharmaceuticals seller in Q2 2022 was Armistice Capital, an estimated $15.3M sold.
Based on aggregated 13F filings for Q2 2022.